Cytokinetics Updates Phase 3 COURAGE-ALS Trial of Reldesemtiv
Most of the initial amyotrophic lateral sclerosis (ALS) patients enrolled in Cytokinetics’ COURAGE-ALS Phase 3 trial testing its experimental…
Articles by Marta Figueiredo, PhD
Oral Edaravone Appears Safe in Patients, Interim Trial Data Show
An oral suspension formulation of edaravone (MT-1186) is safe and well-tolerated in adults with amyotrophic lateral sclerosis (ALS), according…
Patient Enrolled in Phase 2 Trial of Experimental Therapy AP-101
A Phase 2 clinical trial evaluating AL-S Pharma AG’s experimental therapy AP-101 in people with amyotrophic lateral sclerosis…
New Directions in Research, Care Focus of Les Turner ALS Symposium
Recent findings and ongoing efforts to more fully understand the underlying molecular mechanisms of amyotrophic lateral sclerosis (ALS), and…
HEALEY Trial Fully Enrolled for 2 Regimens; Data Expected by Mid-2022
The HEALEY ALS platform trial, the first study to test several therapy candidates for amyotrophic lateral sclerosis (ALS) simultaneously,…
Too Little, Too Much Physical Activity May Shorten Survival
Total job- and leisure-related physical activity over a lifetime is not a risk factor for amyotrophic lateral sclerosis (ALS),…
Dimethyl Fumarate (DMF) Fails to Slow ALS Progression in Trial
Dimethyl fumarate or DMF — an oral therapy approved for multiple sclerosis (MS) — was well-tolerated among adults with…
Early Access to CNM-Au8 Given to Patients Ineligible for HEALEY Trial
Clene, and its wholly owned subsidiary Clene Nanomedicine, have launched an expanded access program (EAP) in the U.S. to…
Seelos’ SLS-005 Cleared as 5th Arm of HEALEY ALS Trial
Seelos Therapeutics’ experimental therapy SLS-005 (trehalose) will serve as the fifth arm of the multi-regimen HEALEY trial for…
ALS Association Supports FDA Reconsidering AMX0035 Decision
The ALS Association is applauding the recent change of heart by the U.S. Food and Drug Administration (FDA) to consider…